CTOs on the Move

Promentis Pharmaceuticals

www.promentispharma.com

 
Promentis Pharmaceuticals, Inc., is a privately held biopharmaceutical company focused on the discovery and development of first-in-class therapies to treat central nervous system (CNS) disorders. Promentis` drug development program is focused on activating a unique target known to restore glutamatergic neurotransmission and imbalances in oxidative stress, key contributors to impaired cortical function linked to multiple CNS disorders. The Company`s lead compound, SXC-2023, is being developed to treat various psychiatric disorders, with an initial focus on an indication that, despite representing a common disorder affecting millions of patients, has no FDA-approved treatment and a high level of patient need.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Funding

Promentis Pharmaceuticals raised $26M on 03/30/2017

Similar Companies

Vitality Biopharma

Vitality has developed a new class of cannabinoid prodrugs (cannabosides), which enable selective delivery of THC and cannabidiol (CBD) to the gastrointestinal tract. Site-specific delivery could enable potent local therapeutic effects while reducing or avoiding the systemic delivery of THC to the brain. Currently, the psychoactivity of THC limits the dose of cannabinoids that can be used for treatment of pain and inflammation. Studies have shown that the cannabinoid system is a potent mediator of pain relief and inflammation, as studies have shown that cannabinoid drugs can in some cases be far more potent than opiates for pain relief, and far more potent than aspirin or corticosteroids for providing anti-inflammatory effects. For example, cannabinoid drugs have been shown to be nearly 10 times as potent as morphine for neuropathic pain relief. Studies have also shown they can be 20 times as potent as aspirin, and twice as potent as corticosteroids for treating inflammation. But currently, the “elephant in the room” remains, which is that the desired potent effects cannot be achieved when high doses of THC enter the bloodstream and brain. Patients are forced to limit their doses, so targeted administration is critical. Our solution goes to the heart of this issue and offers an alternative means to increase the beneficial dosage, right at the site of disease – where it matters most, and relegates the psychoactive nature of the drug to a manageable side effect.

IMA Medical Group

Minnetronix Medical

Since 1996, Minnetronix Medical has accelerated medical device breakthroughs as a design, development and manufacturing partner to leading device companies around the world.

Greater Chattanooga Orthodontics

Let us help make your smile beautiful TODAY! At Greater Chattanooga Orthodontics our commitment to excellence is apparent in all that we do. Our friendly staff can help develop a personalized plan for your specific orthodontic needs. Call TODAY to ...

Rib-X Pharmaceuticals

Rib-X Pharmaceuticals, Inc. is a New Haven, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.